Amarin | AMRN - Sales Revenues

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $49.22M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026